Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 9/20 | 0.41 |
| ▸ | HEXB | P07686 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899707 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL7603703 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL7603749 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL16708418 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL14732693 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL15962116 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL12899657 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL12150224 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL21738820 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 | |
| SCHEMBL8995804 | 1.00 | OGA (0.41) | OGAHEXBLGALS1LGALS3LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | OGA 3830/4885HEXB 3808/4885LGALS1 2623/4885 |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | G6PD, GALE, UGGT1 | OGA 346/4885HEXB 257/4885LGALS1 827/4885 |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | OGA 2229/4885HEXB 2570/4885LGALS1 1303/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | OGA 1458/4885HEXB 1353/4885LGALS1 1725/4885 |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | OGA 2229/4885HEXB 2570/4885LGALS1 1303/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | OGA 3830/4885HEXB 3808/4885LGALS1 2623/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | OGA 2567/4885HEXB 835/4885LGALS1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.